Complement-Activating Multimeric Immunotherapeutic Complexes for HER2-breast cancer immunotherapy
Carole Seguin-Devaux, Bianca Brandus, Jean-Marc Plesseria, Gilles Iserentant, Jean-Yves Servais, Georgia Kanli, Iris Behrmann, Jacques Zimmer, Jacques H M Cohen, Xavier Dervillez
This study develops and tests CoMiX immunotherapeutics that activate complement to kill HER2-positive breast cancer cells, showing significant tumor growth inhibition in xenograft models.
bioRxiv · Feb 2, 2024 · PreprintImmunology